lasmiditan Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antimigraine (5-HT1 receptor agonists) 5351 439239-90-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • lasmiditan
  • lasmiditan succinate
  • COL-144
  • LY-573144
  • reyvow
Reyvow (lasmiditan) is a serotonin (5-HT) 1F receptor agonist for oral administration, bindinding with high affinity to the 5-HT1F receptor. Lasmiditan presumably exerts its therapeutic effects in the treatment of migraine through agonist effects at the 5-HT1F receptor; however, the precise mechanism is unknown.
  • Molecular weight: 377.37
  • Formula: C19H18F3N3O2
  • CLOGP: 1.98
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 62.30
  • ALOGS: -4.33
  • ROTB: 4

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Nov. 10, 2019 FDA ELI LILLY AND CO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dizziness 181.07 104.61 76 328 340338 46345320
Feeling abnormal 111.15 104.61 41 363 125019 46560639
Sedation 106.79 104.61 27 377 22883 46662775

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event

Pharmacologic Action:

SourceCodeDescription
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018490 Serotonin Agents
MeSH PA D017366 Serotonin Receptor Agonists

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Migraine indication 37796009 DOID:6364

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.03 acidic
pKa2 9.43 Basic
pKa3 0.49 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 100MG BASE REYVOW ELI LILLY AND CO N211280 Jan. 31, 2020 RX TABLET ORAL Jan. 31, 2025 NEW CHEMICAL ENTITY
EQ 50MG BASE REYVOW ELI LILLY AND CO N211280 Jan. 31, 2020 RX TABLET ORAL Jan. 31, 2025 NEW CHEMICAL ENTITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 1F GPCR AGONIST Ki 8.65 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE

External reference:

IDSource
439239-92-6 SECONDARY_CAS_RN
4039151 VANDF
C2974932 UMLSCUI
CHEMBL3039520 ChEMBL_ID
CHEMBL3039526 ChEMBL_ID
D10338 KEGG_DRUG
DB11732 DRUGBANK_ID
C554777 MESH_SUPPLEMENTAL_RECORD_UI
11610526 PUBCHEM_CID
3928 IUPHAR_LIGAND_ID
9176 INN_ID
760I9WM792 UNII
2256930 RXNORM
325205 MMSL
d09395 MMSL
018168 NDDF
018169 NDDF
823027003 SNOMEDCT_US
823028008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Reyvow HUMAN PRESCRIPTION DRUG LABEL 1 0002-0265 TABLET 50 mg ORAL Export only 1 sections
Reyvow HUMAN PRESCRIPTION DRUG LABEL 1 0002-0632 TABLET 100 mg ORAL Export only 1 sections
Reyvow HUMAN PRESCRIPTION DRUG LABEL 1 0002-4312 TABLET 50 mg ORAL NDA 32 sections
Reyvow HUMAN PRESCRIPTION DRUG LABEL 1 0002-4491 TABLET 100 mg ORAL NDA 32 sections
Reyvow HUMAN PRESCRIPTION DRUG LABEL 1 0002-4736 TABLET 200 mg ORAL NDA 32 sections